Title: Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces
boulardii supplements on eradication of Helicobacter pylori
Version: 1 Date: 18 Sep 2024
Reviewer:  Dmitry S. Bordin
Reviewer's report:
The presented study is extremely interesting and relevant. In general, it deserves to be published.
At the same time, I would recommend making some corrections to the text:
1. on line 54, the authors refer to the Maastricht V cosensus report. Perhaps they mean Maastricht
VI, published in 2022? The link is not formatted neatly.
2. on lines 134-135, I would ask you to clarify the criteria for the UBT. The authors first indicate
that a positive result is at a DOB level> 4. Then that at delta 4-6 the test was repeated after a
month. For what reason? Apparently, they mean a positive result at a DOB level> 6?
3. on line 208 "ECAB group, including six cases melena". When taking bismuth preparations,
the stool turns black, but this is not melena. The term should be clarified. Melena is a symptom
of bleeding.
4. on line 266 "preventing H. pylori adhesion in the duodenum" - apparently the authors wanted
to say about the antral part of the stomach?
5. The last remark concerns the choice of the dose of amoxicillin in dual therapy with
vonoprazan. Usually it is 3000 mg per day and the duration is 14 days. Probably, with such
a regimen with the addition of S. boulardii the efficiency would significantly exceed 90%.
However, this is discussed in the limitations section and cannot be eliminated by the authors.
Title: Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces
boulardii supplements on eradication of Helicobacter pylori
Version: 1 Date: 18 Sep 2024
Reviewer:  Dmitry S. Bordin
Reviewer's report:
The presented study is extremely interesting and relevant. In general, it deserves to be published.
At the same time, I would recommend making some corrections to the text:
1. on line 54, the authors refer to the Maastricht V cosensus report. Perhaps they mean Maastricht
VI, published in 2022? The link is not formatted neatly.
2. on lines 134-135, I would ask you to clarify the criteria for the UBT. The authors first indicate
that a positive result is at a DOB level> 4. Then that at delta 4-6 the test was repeated after a
month. For what reason? Apparently, they mean a positive result at a DOB level> 6?
3. on line 208 "ECAB group, including six cases melena". When taking bismuth preparations,
the stool turns black, but this is not melena. The term should be clarified. Melena is a symptom
of bleeding.
4. on line 266 "preventing H. pylori adhesion in the duodenum" - apparently the authors wanted
to say about the antral part of the stomach?
5. The last remark concerns the choice of the dose of amoxicillin in dual therapy with
vonoprazan. Usually it is 3000 mg per day and the duration is 14 days. Probably, with such
a regimen with the addition of S. boulardii the efficiency would significantly exceed 90%.
However, this is discussed in the limitations section and cannot be eliminated by the authors.
Please review this paper.
user
Title: Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces
boulardii supplements on eradication of Helicobacter pylori
Version: 1 Date: 18 Sep 2024
Reviewer:  Dmitry S. Bordin
Reviewer's report:
The presented study is extremely interesting and relevant. In general, it deserves to be published.
At the same time, I would recommend making some corrections to the text:
1. on line 54, the authors refer to the Maastricht V cosensus report. Perhaps they mean Maastricht
VI, published in 2022? The link is not formatted neatly.
2. on lines 134-135, I would ask you to clarify the criteria for the UBT. The authors first indicate
that a positive result is at a DOB level> 4. Then that at delta 4-6 the test was repeated after a
month. For what reason? Apparently, they mean a positive result at a DOB level> 6?
3. on line 208 "ECAB group, including six cases melena". When taking bismuth preparations,
the stool turns black, but this is not melena. The term should be clarified. Melena is a symptom
of bleeding.
4. on line 266 "preventing H. pylori adhesion in the duodenum" - apparently the authors wanted
to say about the antral part of the stomach?
5. The last remark concerns the choice of the dose of amoxicillin in dual therapy with
vonoprazan. Usually it is 3000 mg per day and the duration is 14 days. Probably, with such
a regimen with the addition of S. boulardii the efficiency would significantly exceed 90%.
However, this is discussed in the limitations section and cannot be eliminated by the authors.
assistant